4.7 Article

Genetically delivered antibody protects against West Nile virus

期刊

ANTIVIRAL RESEARCH
卷 77, 期 1, 页码 6-13

出版社

ELSEVIER
DOI: 10.1016/j.antiviral.2007.08.010

关键词

WNV; passive immunization; recombinant antibody; gene delivery; adenovirus

资金

  1. NIAID NIH HHS [R03 AI053084, U54 AI057157-05, 5U54 AI057157, R01 AI049258-05, 1R03 AI53084, 1R01 AI049258, R21 AI054538, U54 AI057157, R03 AI053084-03, 5R21 AI054538, R21 AI054538-01, R01 AI049258] Funding Source: Medline
  2. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054538, U54AI057157, R01AI049258, R03AI053084] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Gene-based delivery of recombinant antibody genes is a promising therapeutic strategy offering numerous advantages including sustained antibody levels, better safety profile and lower production cost. Here we describe generation of a recombinant antibody Fc-9E2 comprising a fusion protein between human Fc of IgGI and a single-chain Fv derived from a hybridoma 9E2 secreting a mAb neutralizing West Nile virus (WNV). Fc-9E2 was shown to retain parental mAb's specificity and WNV-neutralizing capacity. Adenovirus-mediated in vivo delivery of the antibody gene resulted in sustained Fc-9E2 serum levels leading to abrogation of lethal WNV infection in an animal model. (C) 2007 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据